Clearmind Medicine announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant step in harnessing generation 3.0 psychedelic compounds, methods of their preparation, and uses thereof in the treatment of addiction and mental disorders. Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
- Clearmind files U.S. patent application for psychedelic-based treatment
- Clearmind CEO says poised to achieve ‘significant milestones’ through 2024
- Clearmind Medicine CEO Issues Letter to Shareholders